NCT07527793 Monitoring Changes in Blood Circulating Metabolites Using Minimally Invasive Techniques
| NCT ID | NCT07527793 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Örebro University, Sweden |
| Condition | Healthy Participants |
| Study Type | INTERVENTIONAL |
| Enrollment | 35 participants |
| Start Date | 2026-01-21 |
| Primary Completion | 2026-05-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 35 participants in total. It began in 2026-01-21 with a primary completion date of 2026-05-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study investigates short-term intra- and inter-individual variability in human blood metabolism under real-life conditions. Using minimally invasive finger-prick blood sampling, dietary records, and wearable devices, we will longitudinally monitor blood-circulating metabolites and glucose levels in healthy individuals over a four-week period without dietary or lifestyle intervention. The study focuses on metabolic transitions between pre- and postprandial states during habitual daily activities and routine meals. Mass spectrometry-based metabolomics will be used to characterize metabolite profiles and their associations with diet, physical activity, sleep, and stress. In parallel, the study evaluates the feasibility of microsampling approaches, wearable-derived physiological data, and isotope-labelled standards for robust and cost-effective metabolite quantification. The results will inform the design of larger longitudinal studies using minimally invasive blood sampling in non-controlled settings.
Eligibility Criteria
Inclusion Criteria: 1. Age: 18-65 years old 2. Body Mass Index (BMI): 18.5-29.9 kg/m2 3. Weight stability within the previous 3 months (self-reported). 4. Positive intention to maintain usual routine physical activity and eating habits during the study. Exclusion Criteria: 1. Presence of acute chronic diseases, inflammatory or functional gastrointestinal disorders, or any diagnosed disease condition that disrupt daily routine activities. 2. Routine use medications or supplements that could potentially interfere with the study outcomes 3. History of eating disorder 4. Recent use of antibiotic medication within the last 3 months prior to the first visit 5. Active efforts to lose weight 6. Smoking 7. Consumption of alcoholic drinks exceeding nine standard cups per week and/or more than three standard cups per occasion
Contact & Investigator
Matej Oresic, Ph.D.
PRINCIPAL INVESTIGATOR
School of Medical Sciences, Orebro University
Frequently Asked Questions
Who can join the NCT07527793 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Healthy Participants. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07527793 currently recruiting?
Yes, NCT07527793 is actively recruiting participants. Contact the research team at anh-hoang.nguyen@oru.se for enrollment information.
Where is the NCT07527793 trial being conducted?
This trial is being conducted at Örebro, Sweden.
Who is sponsoring the NCT07527793 clinical trial?
NCT07527793 is sponsored by Örebro University, Sweden. The principal investigator is Matej Oresic, Ph.D. at School of Medical Sciences, Orebro University. The trial plans to enroll 35 participants.